Afegeix-ho a l'agenda (iCal)
El proper 19 de maig a les 12h, l'Aula Magna del Campus Clínic acollirà el segon dels seminari del Cicle Continuat de Conferències de la Facultat de Medicina i Ciències de la Salut.
El seminari porta per títol "Identifying and overcoming resistance to melanoma therapies" i estarà a càrrec del Dr. Rizwan Haq, Assistant Professor, Medicine, Harvard Medical School, Principal Investigator, Medical Oncology Dana-Farber Cancer Institute and Associate Member, Cancer Biology, Broad Institute of MIT and Harvard.
"Dr. Haq is a graduate of the University of Toronto, where he completed his B.Sc. (Hon), and MD/PhD. His PhD was at the Ontario Cancer Institute/Princess Margaret Hospital in the laboratory of Dr Brent Zanke. He completed his clinical training in internal medicine at The Johns Hopkins Hospital in Baltimore, followed by medical oncology training at Dana-Farber Cancer Institute and Massachusetts General Hospital. He joined the laboratory of Dr David E. Fisher, where he conducted translational work in the melanoma; and was an attending oncologist at Massachusetts General Hospital.
He was recruited back to Dana-Farber Cancer Institute in 2014. His research focuses on resistance to melanoma therapies, including targeted agents and immunotherapies. He has been a contributing author of numerous high profile publications, including those published in Cancer Cell, Nature, Proceedings of the National Academy of Sciences USA. At Dana-Farber Cancer Institute, Dr. Haq devotes part of his time to developing the next generation of melanoma therapeutics and translating them to innovative investigator-initiated clinical trials. His clinical practice is dedicated to patients with melanoma"